Literature DB >> 15148102

Is high mole count a marker of more than melanoma risk? Eczema diagnosis is associated with melanocytic nevi in children.

Robert P Dellavalle1, Eric J Hester, Deborah L Stegner, Ann M Deas, Theresa R Pacheco, Stefan Mokrohisky, Joseph G Morelli, Lori A Crane.   

Abstract

BACKGROUND: The number of melanocytic nevi is the best single marker of increased melanoma risk. In a previous study, adults with severe eczema were reported to have significantly fewer nevi than adults without eczema. OBSERVATIONS: In a nested case-control design within a randomized, controlled interventional trial of additional sun protection vs standard care in 269 children, a history of eczema was reported by the parents of 44 (16%) of the children. More nevi were found in children with a parental report of previous eczema diagnosis than in children without reported eczema (median, 7.5 nevi vs 5.0 nevi; P =.01). Eczema diagnosis was most significantly associated with more melanocytic nevi in children with lightly pigmented skin (8.5 nevi vs 6.0 nevi; P <.001). In multivariate logistical regression analysis, including assessment of hair color, sun protection practices, and study assignment (intervention vs standard care), eczema status remained significantly predictive of nevi number in children (P <.001).
CONCLUSIONS: In contrast to a previous study that associated severe eczema with fewer nevi in adults, in the present study children with a reported history of eczema had more nevi than children without a reported history of eczema.

Entities:  

Mesh:

Year:  2004        PMID: 15148102     DOI: 10.1001/archderm.140.5.577

Source DB:  PubMed          Journal:  Arch Dermatol        ISSN: 0003-987X


  1 in total

1.  Risk of squamous cell carcinoma of the skin in relation to IgE: a nested case-control study.

Authors:  Joseph L Wiemels; John K Wiencke; Zhongze Li; Christian Ramos; Heather H Nelson; Margaret R Karagas
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2011-09-23       Impact factor: 4.254

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.